Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-L-fucosidase 1 is a lysosomal glycoside hydrolase (EC 3.2.1.51) encoded by the FUCA1 gene. It hydrolyzes terminal L-fucose residues from glycans bound to glycoproteins and glycolipids, serving a crucial role in cellular glycan degradation. Genetic deficiency of this enzyme leads to fucosidosis, a lysosomal storage disorder characterized by progressive neurological decline, organomegaly, and characteristic skin and skeletal findings[2]. Structurally, alpha-L-fucosidase 1 belongs to the CAZy GH29 family and exhibits a barrel-fold architecture, with catalytic activity reliant on conserved nucleophile and acid/base residues[1][4]. Variant isoforms exist in microbes, but the human enzyme’s clinical significance stems primarily from its role in cellular metabolism and inherited disease, with ongoing research into biomarker and biotechnological applications.
Inhibitors (if developed) would block L-fucose cleavage, causing increased glycan accumulation; enzyme replacement or gene therapy aims to restore function in deficient patients.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-L-fucosidase 1 (FUCA1).